

ANTIVIRAL DRUGS

Anti-Influenza Drugs (RNA Virus)

| Drug(s) | Mechanism of Action | Clinical Use | Toxicity |
|------------------------------------|--|---|--|
| Amantadine, Rimantadine | Blocks attachment, penetration, and uncoating of influenza A virus. | Prophylaxis of influenza A (no longer useful due to resistance); adjuvant for Parkinsonism(tolerance) | Nervousness, insomnia, seizures (overdose), atropine-like effects. |
| Oseltamivir, Zanamivir | Inhibits neuraminidases of influenza A & B, preventing release of viral particles. | Prevention and treatment of influenza A & B. | Not specified. |

Anti-Herpetic Drugs (DNA Virus)

| Drug(s) | Mechanism of Action | Clinical Use | Toxicity |
|---|---|---|--|
| Acyclovir, Famciclovir, Valacyclovir | Guanosine analogs → phosphorylated to triphosphates → inhibit viral DNA polymerase → chain termination. | Herpes simplex, varicella-zoster virus; prophylaxis in immunocompromised. | Crystalluria, nephropathy (maintain hydration). |
| Ganciclovir | Phosphorylated by CMV kinase → inhibits DNA polymerase. | Treatment/prophylaxis of CMV (immunocompromised). | Myelosuppression, nephropathy. |
| Foscarnet | Directly inhibits viral DNA polymerase, RNA polymerase, and HIV reverse transcriptase (no activation required). | Resistant CMV or HSV infections. | Nephrotoxicity, electrolyte imbalances → seizures. |

Anti-HIV Drugs

A. Fusion Inhibitors

| Drug(s) | Mechanism of Action | Toxicity |
|-------------|--|---|
| Enfuvirtide | Binds gp41 (viral) → blocks viral and cellular membrane fusion. | Injection site reaction, hypersensitivity, bacterial pneumonia. |
| Maraviroc | Binds CCR5 (host receptor) → prevents virus entry into CD4+ cells. | Cough, diarrhea, muscle/joint pain. |

B. Reverse Transcriptase Inhibitors (RTIs)

| Drug(s) | Mechanism of Action | Clinical Use and notes | Toxicity |
|---|---|---|--|
| NRTIs (Zidovudine, lamivudine, didanosine, tenofovir) | Phosphorylated by host kinases → inhibit reverse transcriptase → DNA chain termination. | Core HAART component; vertical transmission prophylaxis . Crosses BBB, excreted by liver | Bone marrow depression (reversed by G-CSF and erythropoietin), peripheral neuropathy, lactic acidosis. |
| NNRTIs (Efavirenz, etravirine) | Bind reverse transcriptase (non-competitive) → inhibit DNA synthesis. | Part of HAART regimens. Contra indicated in pregnancy | Rash, hepatotoxicity; vivid dreams (Efavirenz, contraindicated in pregnancy). |

C. Integrase Inhibitors

| Drug(s) | Mechanism of Action | Notes |
|---------------------------|--|--|
| Raltegravir, Elvitegravir | Inhibit integration of viral genome into host DNA. | Used as part of HAART (2 NRTIs + another agent). |

D. Protease Inhibitors (PIs)

| Drug(s) | Mechanism of Action | Toxicity |
|----------------------------------|--|--|
| Atazanavir, Lopinavir, Ritonavir | Inhibits HIV protease → prevents viral maturation. | Hyperglycemia, lipodystrophy, nausea, diarrhea, drug-drug reaction (because they inhibit CYP450) |

Done by we'am abdullah